Literature DB >> 24445999

A dual role for autophagy in a murine model of lung cancer.

Shuan Rao1, Luigi Tortola1, Thomas Perlot1, Gerald Wirnsberger1, Maria Novatchkova1, Roberto Nitsch1, Peter Sykacek2, Lukas Frank3, Daniel Schramek1, Vukoslav Komnenovic1, Verena Sigl1, Karin Aumayr1, Gerald Schmauss1, Nicole Fellner4, Stephan Handschuh5, Martin Glösmann5, Pawel Pasierbek1, Michaela Schlederer6, Guenter P Resch4, Yuting Ma7, Heng Yang7, Helmuth Popper8, Lukas Kenner6, Guido Kroemer9, Josef M Penninger1.   

Abstract

Autophagy is a mechanism by which starving cells can control their energy requirements and metabolic states, thus facilitating the survival of cells in stressful environments, in particular in the pathogenesis of cancer. Here we report that tissue-specific inactivation of Atg5, essential for the formation of autophagosomes, markedly impairs the progression of KRas(G12D)-driven lung cancer, resulting in a significant survival advantage of tumour-bearing mice. Autophagy-defective lung cancers exhibit impaired mitochondrial energy homoeostasis, oxidative stress and a constitutively active DNA damage response. Genetic deletion of the tumour suppressor p53 reinstates cancer progression of autophagy-deficient tumours. Although there is improved survival, the onset of Atg5-mutant KRas(G12D)-driven lung tumours is markedly accelerated. Mechanistically, increased oncogenesis maps to regulatory T cells. These results demonstrate that, in KRas(G12D)-driven lung cancer, Atg5-regulated autophagy accelerates tumour progression; however, autophagy also represses early oncogenesis, suggesting a link between deregulated autophagy and regulatory T cell controlled anticancer immunity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24445999     DOI: 10.1038/ncomms4056

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  205 in total

Review 1.  Autophagy, Metabolism, and Cancer.

Authors:  Eileen White; Janice M Mehnert; Chang S Chan
Journal:  Clin Cancer Res       Date:  2015-11-15       Impact factor: 12.531

Review 2.  The Autophagy Lysosomal Pathway and Neurodegeneration.

Authors:  Steven Finkbeiner
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-03-02       Impact factor: 10.005

3.  Salidroside protects cortical neurons against glutamate-induced cytotoxicity by inhibiting autophagy.

Authors:  Wei-Yong Yin; Qiang Ye; Huan-Jie Huang; Nian-Ge Xia; Yan-Yan Chen; Yi Zhang; Qiu-Min Qu
Journal:  Mol Cell Biochem       Date:  2016-06-29       Impact factor: 3.396

4.  Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells.

Authors:  Erika Vacchelli; Michaela Semeraro; Julien Adam; Peggy Dartigues; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2015-07-01       Impact factor: 8.110

5.  Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy.

Authors:  Sylvain Ladoire; David Enot; Fabrice Andre; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2015-08-31       Impact factor: 8.110

6.  HIV-1 Nef promotes cell proliferation and microRNA dysregulation in lung cells.

Authors:  Maryline Santerre; Wissam Chatila; Ying Wang; Ruma Mukerjee; Bassel E Sawaya
Journal:  Cell Cycle       Date:  2019-01-06       Impact factor: 4.534

Review 7.  Drugging the undruggable RAS: Mission possible?

Authors:  Adrienne D Cox; Stephen W Fesik; Alec C Kimmelman; Ji Luo; Channing J Der
Journal:  Nat Rev Drug Discov       Date:  2014-10-17       Impact factor: 84.694

Review 8.  Development of autophagy inducers in clinical medicine.

Authors:  Beth Levine; Milton Packer; Patrice Codogno
Journal:  J Clin Invest       Date:  2015-01-02       Impact factor: 14.808

9.  Spermidine reduces cancer-related mortality in humans.

Authors:  Federico Pietrocola; Francesca Castoldi; Oliver Kepp; Didac Carmona-Gutierrez; Frank Madeo; Guido Kroemer
Journal:  Autophagy       Date:  2018-10-29       Impact factor: 16.016

10.  Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.

Authors:  Huiyu Ren; Nicole A Bakas; Mitchell Vamos; Apirat Chaikuad; Allison S Limpert; Carina D Wimer; Sonja N Brun; Lester J Lambert; Lutz Tautz; Maria Celeridad; Douglas J Sheffler; Stefan Knapp; Reuben J Shaw; Nicholas D P Cosford
Journal:  J Med Chem       Date:  2020-11-17       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.